Literature DB >> 23429915

Trends in the lifetime risk of COPD exacerbation requiring hospitalisation.

Jesper Lykkegaard1, René dePont Christensen, Jesper Rømhild Davidsen, Henrik Støvring, Morten Andersen, Jens Søndergaard.   

Abstract

This study aimed to estimate time trends in the lifetime risk of hospitalisation with exacerbation of chronic obstructive pulmonary disease (COPD) in Denmark. During the period from 1994 to 2008, a register-based cohort study was conducted covering each subject in the entire population of Denmark (5.18 million in 2008). Based on previously validated diagnosis codes, all COPD hospitalisations were identified. Individual retrospective review periods of 8 years were used to determine first-time hospitalisations. From year 2002 to 2008, all first-time COPD hospitalised subjects aged ≥30 years were identified. The calculation of lifetime risk was based on age- and sex-specific first-time COPD hospitalisation rates and rates of COPD hospitalisation-free survival, assuming them to be calendar time stationary. The study included 23.9 million person-years of risk time and identified 48 959 first-time COPD hospitalisations. For 30-year-olds in Denmark, the lifetime risk of COPD hospitalisation was 12.0% (95% CI 11.9-12.2) for females and 10.9% (95% CI 10.8-11.1) for males. Trends were generally equal in both sexes. During the period from 2002 to 2008, the rate of first-time COPD hospitalisations decreased, while the survival of never COPD hospitalised subjects increased. In consequence, the lifetime risk of COPD hospitalisation remained constant.

Entities:  

Mesh:

Year:  2013        PMID: 23429915     DOI: 10.1183/09031936.00129312

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  3 in total

1.  General practitioners' home visit tendency and readmission-free survival after COPD hospitalisation: a Danish nationwide cohort study.

Authors:  Jesper Lykkegaard; Pia V Larsen; Maja S Paulsen; Jens Søndergaard
Journal:  NPJ Prim Care Respir Med       Date:  2014-11-27       Impact factor: 2.871

2.  DNA methylation signature of chronic low-grade inflammation and its role in cardio-respiratory diseases.

Authors:  Matthias Wielscher; Pooja R Mandaviya; Brigitte Kuehnel; Roby Joehanes; Rima Mustafa; Oliver Robinson; Yan Zhang; Barbara Bodinier; Esther Walton; Pashupati P Mishra; Pascal Schlosser; Rory Wilson; Pei-Chien Tsai; Saranya Palaniswamy; Riccardo E Marioni; Giovanni Fiorito; Giovanni Cugliari; Ville Karhunen; Mohsen Ghanbari; Bruce M Psaty; Marie Loh; Joshua C Bis; Benjamin Lehne; Nona Sotoodehnia; Ian J Deary; Marc Chadeau-Hyam; Jennifer A Brody; Alexia Cardona; Elizabeth Selvin; Alicia K Smith; Andrew H Miller; Mylin A Torres; Eirini Marouli; Xin Gào; Joyce B J van Meurs; Johanna Graf-Schindler; Wolfgang Rathmann; Wolfgang Koenig; Annette Peters; Wolfgang Weninger; Matthias Farlik; Tao Zhang; Wei Chen; Yujing Xia; Alexander Teumer; Matthias Nauck; Hans J Grabe; Macus Doerr; Terho Lehtimäki; Weihua Guan; Lili Milani; Toshiko Tanaka; Krista Fisher; Lindsay L Waite; Silva Kasela; Paolo Vineis; Niek Verweij; Pim van der Harst; Licia Iacoviello; Carlotta Sacerdote; Salvatore Panico; Vittorio Krogh; Rosario Tumino; Evangelia Tzala; Giuseppe Matullo; Mikko A Hurme; Olli T Raitakari; Elena Colicino; Andrea A Baccarelli; Mika Kähönen; Karl-Heinz Herzig; Shengxu Li; Karen N Conneely; Jaspal S Kooner; Anna Köttgen; Bastiaan T Heijmans; Panos Deloukas; Caroline Relton; Ken K Ong; Jordana T Bell; Eric Boerwinkle; Paul Elliott; Hermann Brenner; Marian Beekman; Daniel Levy; Melanie Waldenberger; John C Chambers; Abbas Dehghan; Marjo-Riitta Järvelin
Journal:  Nat Commun       Date:  2022-05-03       Impact factor: 17.694

3.  Isoliquiritigenin Inhibits Cigarette Smoke-Induced COPD by Attenuating Inflammation and Oxidative Stress via the Regulation of the Nrf2 and NF-κB Signaling Pathways.

Authors:  Duo Yu; Xueshibojie Liu; Guangxin Zhang; Zhihui Ming; Tiejun Wang
Journal:  Front Pharmacol       Date:  2018-09-20       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.